http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5219999-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40114fb3c8d4f80649201a3c49d9da8b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cebc9740ef706cde29e885504f274ffa
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-065
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00
filingDate 1991-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 1993-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6388deb50c04c2dcc0b023a0acf0478
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b232610beb20a9a43bd545fa011a525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f51f61344afc21c1cffd59d9523fddb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e884e5da5530ac1086e787d54ffa1edb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98d6febf7772b3b4bf5c466c3e7828aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84dc144337c15d3d0d9640dca39c3571
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a20696e0db96e2c4eff3568ce9e9dcb
publicationDate 1993-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-5219999-A
titleOfInvention Immunoglobulin g and process for the production thereof
abstract Crude immunoglobulin G isolated from human blood plasma is treated according to a conventional technique (such as the tricalcium phosphate adsorption method) to remove aggregates therefrom to such an extent that they are not detectable by gel filtration analysis. In order to produce an aqueous solution of immunoglobulin G having a reduced anticomplementary activity, the resulting solution is then filtered through a porous polyolefin membrane having a pore size larger than the molecular size of immunoglobulin G, in the presence of a stabilizer having surface activity. The aqueous solution of immunoglobulin G so produced is suitable for use in intravenous injection because its anticomplementary activity is low.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10238325-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0973549-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11291393-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10028690-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10287314-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE40070-E
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9630988-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014309558-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9517026-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006177909-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014309556-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013197200-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE41555-E
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10791975-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10590164-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE44558-E
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE41595-E
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5429746-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9650411-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9549700-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE43655-E
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10342471-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9597028-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11634457-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9380972-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10136849-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10080516-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9408568-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9380973-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10827965-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10925530-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9096648-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10194851-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10154808-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9808192-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9833182-B2
priorityDate 1990-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4708799-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0246579-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5022988-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-2026076-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0270025-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0085747-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0268973-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4933092-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-8606727-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129363337
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128990957
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7996
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409442
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15918561
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5366546

Total number of triples: 77.